Elim Biopharmaceuticals

What Elim Biopharmaceuticals does

Elim Biopharmaceuticals is a privately held life science services company headquartered in Hayward, California, operating for more than 20 years in the San Francisco Bay Area. The company provides a vertically integrated suite of molecular biology services to biotech and pharmaceutical companies, academic medical centers, and clinical laboratories, including Sanger DNA sequencing, next-generation sequencing (NGS) on Illumina and Ion Torrent platforms, oligonucleotide synthesis, peptide synthesis, plasmid DNA purification, and bioanalytical LC/MS/MS services supporting PK/PD, ADME, and biomarker studies across preclinical and clinical phases. Elim also sells two branded catalog products — the RightOn Cancer Sequencing Kit (a 1,000-gene NGS panel built on proprietary liquid phase hybridization target enrichment) and the RightOn DNA Library Prep Kit for Illumina workflows.

The business operates on a primarily transactional revenue model: most services are priced per reaction or per project via quote, with only one publicly disclosed price point ($15 per plasmid for the whole plasmid sequencing service). Customer acquisition runs through a direct-to-researcher model anchored by the company's website and a proprietary online ordering portal (order.elimbio.com), supplemented by email-based quotation handling, phone sales, and free local courier pickup and delivery across the San Francisco Bay Area. Out-of-area and international customers ship samples via FedEx. Elim has established research collaborations with Massachusetts General Hospital's Pathology Department for cancer panel validation and maintains technology alignment with both Illumina and Thermo Fisher Scientific (Ion Torrent) sequencing ecosystems. The company positions speed — overnight or same-day turnaround across multiple service lines — as its primary differentiator over larger CRO competitors.

Name

Elim Biopharmaceuticals

Legal name

Elim Biopharmaceuticals, Inc.

Website

https://elimbio.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Elim Biopharmaceuticals is a privately held Bay Area CRO providing DNA sequencing, NGS, oligo and peptide synthesis, plasmid purification, and bioanalytical mass spectrometry services to biotech, pharma, academic, and clinical research customers, supplemented by branded RightOn NGS library prep and cancer panel kits.

Ownership category

akta.pro rank

Product category

Life Science Molecular Biology Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD)

akta.pro secondary industries

mRNA/LNP & Nucleic Acid Therapeutics CDMO (HLAGABAF), Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF)

Keywords

• Molecular biology services
• DNA sequencing services
• Peptide synthesis services
• Oligonucleotide synthesis
• Bioanalytical mass spectrometry

Headquarters

HQ city

Hayward

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Infrastructure, Marketing or Sales

Revenue model

1. DNA Sequencing Services: Elim generates revenue from Sanger DNA sequencing services, offering a range of read lengths, quality tiers, and turnaround options. Revenue is transaction-based per reaction, with premium pricing for same-day turnaround and specialized sample types (BAC DNA, genomic DNA). Online ordering system manages order-to-delivery workflow.
2. DNA Purification Services: Elim offers plasmid DNA purification at multiple scales (mini, midi, maxi, mega, giga, and custom 1mg–multi-gram preparations). Revenue is per-reaction/per-preparation, with pricing varying by scale, endotoxin level, and whether sequencing verification or enzyme digestion is included. Endotoxin-free preparations command premium pricing.
3. Whole Plasmid Sequencing: Whole Plasmid Sequencing is offered at a flat rate of $15 per plasmid, covering plasmids up to 25 kb. This is a unit-priced, transaction-fee model with overnight turnaround. Customers submit samples locally or by mail and receive results the next business day.
4. Oligo Synthesis: Oligo synthesis revenue is based on synthesis scale (25 nmol, 50 nmol, 0.2 µmol, 1 µmol, multi-µmol), length, and purification level (desalt, PAGE, HPLC). Base oligos under 35 bases without modifications are available with overnight delivery. Higher scales and modifications (biotin, fluorescent labels, etc.) incur additional charges. Internal transfers of oligos for sequencing are provided free to existing customers.
5. Peptide Synthesis: Peptide synthesis revenue is driven by peptide length, purity level (crude, >70%, >80%, >90%, >95%, >98%), scale (1–5 mg to >100 mg), and modifications (fluorescent labeling, phosphorylation, cyclization, PEG, etc.). Overnight service for crude 10mer or less is available. Stable isotope-labeled (SIL) peptides, peptide arrays, and custom modifications are premium offerings. Revenue per order scales with customization complexity.
6. Next Generation Sequencing (NGS) Services: Elim provides NGS services across Illumina (HiSeq 2500, MiSeq) and Ion Torrent (Ion PGM, Ion Proton) platforms. Revenue is generated per lane, per run, or per sample, with pricing dependent on platform, read length, output, and application. Bioinformatics support, library prep, and enrichment are bundled or add-on services.
7. Bioanalytical & Mass Spec Services: Bioanalytical services cover small molecule quantification, large molecule/protein quantification, biomarker assays, dry blood spot analysis, and support for PK/PD/ADME/metabolite ID studies across preclinical and clinical phases. Revenue is project-based, typically quoted per study or per sample batch, with turnaround times varying by study complexity.
8. RightOn DNA Library Prep Kits (Product Sales): Elim sells RightOn DNA Library Prep Kits in pack sizes of 6, 24, or 96 reactions (both standard and low input variants). These are catalog products sold directly to research customers, constituting a product revenue stream separate from services. Pricing is per kit, with volume discounts available.
9. RightOn Cancer Sequencing Kits (Product Sales): RightOn 1000 Cancer Genes NGS Kits are sold as catalog products (6, 24, or 96 reactions) for Illumina-based cancer panel sequencing. Available in standard (250ng input) and low input (≤100ng input) variants. These are research-use-only kits sold directly to labs, with special pricing offered for research collaborators.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Elim Biopharmaceuticals is a life science service company providing molecular biology and bioanalytical services to the biotech, pharmaceutical, and medical research communities. Its core offerings span DNA purification, Sanger DNA sequencing, whole plasmid sequencing, custom oligonucleotide synthesis, custom peptide synthesis (including arrays and stable isotope-labeled peptides), next-generation sequencing on Illumina and Ion Torrent platforms, and LC/MS/MS-based bioanalytical quantification. The company also sells two proprietary catalog reagent kits — the RightOn DNA Library Prep Kit and the RightOn Cancer Sequencing Kit — under the RightOn brand.

Product overview

Elim Biopharmaceuticals is a life science service company offering a portfolio of molecular biology services and products for biotech and pharmaceutical research. The product portfolio includes two main branded kit products—RightOn Cancer Sequencing Kit (targeting 1,000 cancer genes for NGS-based cancer profiling) and RightOn DNA Library Prep Kit (for Illumina sequencing library construction)—along with seven service offerings: DNA Purification, DNA Sequencing, Whole Plasmid Sequencing, Oligo Synthesis, Peptide Synthesis, Next Generation Sequencing, and Bioanalytical & Mass Spec Services. The RightOn kit products provide reagents for library prep and target enrichment, while the service offerings cover the full workflow from sample preparation through sequencing and analysis.

Differentiator

Problem solved

Functional benefit

Products and services

• DNA Purification Services

Quantifiable outcome

• 100x minimum coverage for >98% of targeted bases with 5–6 Gb sequencing data per sample
• +6 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Three partnerships are on record, tiered notable and core.

• Massachusetts General Hospital (MGH) — Pathology DepartmentnotableStrategic or Co-development PartnerElim collaborated with the Pathology Department of Massachusetts General Hospital to validate the performance of the RightOn Cancer Sequencing Kits. Testing produced excellent results, which are used in promotional materials. MGH is a leading academic medical center, and this collaboration serves as a reference validation for Elim's cancer sequencing product. The partnership extends to offering research collaborators special pricing on RightOn Cancer Sequencing Kits and co-authoring publication opportunities.
• IlluminacoreTechnology or IntegrationElim's RightOn DNA Library Prep Kits and RightOn Cancer Sequencing Kits are designed for compatibility with Illumina multiplexing platforms (HiSeq, MiSeq) and include Illumina indices. The RightOn NGS Library Prep Kit v1 is explicitly validated for Illumina workflows. This is a core technology partnership — Elim's proprietary kit products are built on and compatible with Illumina's sequencing ecosystem.
• Ion Torrent (Thermo Fisher Scientific)coreTechnology or IntegrationElim's NGS services are offered on both Illumina and Ion Torrent platforms (Ion PGM and Ion Proton). The company's service infrastructure supports both major sequencing ecosystems, with Ion Proton capable of delivering up to 10 Gb per run. This broadens the addressable market and allows customers to choose their preferred sequencing platform.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• BioSynthesis Inc. US-based oligo and peptide synthesis services company with similar focus on custom synthesis and rapid turnaround. Most comparable mid-sized competitor to Elim in the custom synthesis services segment.
• GenScript: Global life science services company offering gene synthesis, peptide synthesis, plasmid preparation, and protein services. Most direct peer to Elim across the molecular biology services stack, but operates at vastly larger scale with CDMO-grade capabilities.
• Integrated DNA Technologies (IDT): Leading oligonucleotide synthesis provider, now part of Danaher. Directly comparable to Elim's oligo synthesis service and overlaps on NGS-adjacent offerings, with similar same-day/overnight turnaround expectations in research markets.
• Twist Bioscience: DNA synthesis and NGS target enrichment company with proprietary silicon-based DNA writing platform. Overlaps with Elim on oligo synthesis and NGS panel products (target enrichment), but operates at significantly greater scale with public-company backing.
• Genewiz (Azenta Life Sciences): Sanger and NGS sequencing services company acquired by Azenta. Directly competes with Elim on DNA sequencing services and NGS offerings, with comparable turnaround tiers and academic/biotech customer focus.
• BioBasic: Custom oligo and peptide synthesis company serving academic and biotech research customers globally. Comparable service offering and customer base, with similar emphasis on speed and custom modifications.
• Quintara Biosciences: DNA sequencing services company in the San Francisco Bay Area offering Sanger and NGS services. Directly comparable regional peer focused on research customer base with similar speed-driven value proposition.
• ACGT Inc. DNA sequencing and genomics services company focused on academic and biotech research customers with rapid turnaround offerings. Comparable service portfolio and customer base, especially in Sanger sequencing.

Broad incumbents

• Eurofins Genomics: Large global genomics services provider within Eurofins Scientific, offering DNA sequencing, oligo synthesis, and gene synthesis. Comparable to Elim's service portfolio but serves global pharma at much larger scale and broader reach.

Regional players

• Eurogentec: European-based oligonucleotide and peptide synthesis CDMO, part of Kaneka. Comparable custom synthesis services but primarily serves European pharma/biotech market rather than US Bay Area research customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Elim Biopharmaceuticals